AuriGen Medical develops the Zenith left atrial appendage occlusion (LAAO) device, which utilizes independent anchors for optimal placement and intra-procedural leak analysis to enhance patient safety during implantation. This technology addresses the risk of stroke in patients with atrial fibrillation by effectively sealing off the left atrial appendage.
Funding
$3.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Patients with atrial fibrillation face an increased risk of stroke due to blood clot formation in the left atrial appendage (LAA). Current left atrial appendage occlusion (LAAO) devices may not always achieve optimal placement or complete sealing, potentially compromising patient safety during implantation.
Solution
AuriGen Medical is developing the Zenith LAAO device, which utilizes independent anchors to allow for precise placement and repositioning within the heart. The device incorporates intra-procedural leak analysis, enabling physicians to assess the seal quality during the procedure and optimize placement to minimize leaks. This technology aims to provide a more secure and effective method for sealing off the left atrial appendage, reducing the risk of stroke in patients with atrial fibrillation. The Zenith device is designed to enhance patient safety and improve outcomes in LAAO procedures.
Target Audience
The primary target audience includes interventional cardiologists and electrophysiologists specializing in structural heart disease, as well as patients with atrial fibrillation at risk of stroke.
Features
- Independent anchors for optimized placement and repositioning
- Intra-procedural leak analysis to ensure complete sealing
- Designed to minimize the risk of injury to the heart during implantation
- Intended to reduce the risk of stroke in patients with atrial fibrillation